CeNeS has drug discovery programmes targeted at a range of CNS disorders. The synergies between CeNeS and the recently acquired US-based company Cambridge NeuroScience enhance the enlarged group s discovery and development portfolio considerably. In addition to G-protein coupled receptors like the dopamine D1 receptor, a major focus of the research at CeNeS is on ion channels. Ion channels are the basis of nerve conduction in the CNS and modulators of ion channel function have important therapeutic potential in a variety of CNS disorders. The group has a sales and marketing infrastructure with a broad portfolio of products targeting with its own sales force the US, Canada, UK, Republic of Ireland, France, Germany, Italy, including plans to expand in Spain and to add Japan by 2004.
Shire intends to cover other significant pharmaceutical markets indirectly through distributors.
We have already appointed distributors in Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea, and Thailand. Shire is actively seeking to acquire further marketed products and development projects to enhance the potential for future growth. All rights reserved. Reproduction or copying of images prohibited.